- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2012-2013 in major regions.
- Why 3/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. NovoThirteen is already approved and marketed. It is a tiny, niche product within Novo Nordisk, a company with a market capitalization exceeding $350 billion whose value is driven by Ozempic, Wegovy, and the broader diabetes/obesity portfolio. Any news about this drug would have negligible impact on NVO's share price.
No near-term binary catalysts exist for NovoThirteen. The drug is already approved and marketed in major regions (US, EU, Japan, Australia, Canada) for an ultra-rare indication. Watch for any potential label expansion or new competition in the factor XIII space, but neither appears imminent. This drug has no material impact on NVO's investment thesis.
Price Chart
Executive Summary
NovoThirteen (generic name catridecacog, sold as Tretten in the US) is an already-approved, marketed recombinant clotting factor for the ultra-rare congenital factor XIII A-subunit deficiency. It was approved in the EU in September 2012 and in the US in December 2013. The drug is a very small, niche product within Novo Nordisk's massive portfolio, which is dominated by diabetes (Ozempic) and obesity (Wegovy) franchises. No upcoming regulatory catalysts, label expansions, or material news were identified. For a Novo Nordisk investor, this drug is a negligible contributor to the company's value and earnings.
How It Works
NovoThirteen is a manufactured (recombinant) version of a naturally occurring human blood-clotting protein called factor XIII. In patients with a rare inherited bleeding disorder (congenital factor XIII A-subunit deficiency), the body does not produce enough functional factor XIII to form stable blood clots. NovoThirteen replaces the missing protein, helping blood clots form properly and preventing excessive bleeding episodes.
Trial Status
NovoThirteen (catridecacog) received marketing authorization in the European Union in September 2012 and FDA approval in the US (as Tretten) in December 2013. It is also approved in Australia (2013), Canada, Japan, and Switzerland. The drug is commercially available for routine prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency. A post-marketing observational study is ongoing in the EU.
The Two-Sided Case
Upcoming Catalysts
- No near-term binary catalysts identified. The drug is already approved and marketed with no pending regulatory decisions or pivotal trial readouts.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report